Oncimmune Holdings Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Martin Gouldstone

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	4.3yrs
Promedio de permanencia en la Junta Directiva	3.5yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Martin Gouldstone (57 yo)

less than a year

Permanencia

Mr. Martin John Gouldstone is Chief Executive Officer and Director of Oncimmune Holdings plc from August 1, 2023. He serves as Non-Executive Director of ValiRx Plc since April 22, 2024. He is Independent N...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Martin Gouldstone	CEO & Director	less than a year	sin datos	sin datos
Martin Hudson	Finance Director	less than a year	sin datos	sin datos
Ron Kirschner	COO, General Counsel & Company Secretary	4.1yrs	sin datos	0.0022% £ 461.2
Tariq Sethi	Chief Scientific Officer	4.6yrs	sin datos	sin datos
Cléa Rosenfeld	Head of Investor Relations	4.8yrs	sin datos	sin datos
Maarten Brusse	Chief Commercial Officer of Asia	7.7yrs	sin datos	sin datos

4.3yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de OCY se considera experimentado (4.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Martin Gouldstone	CEO & Director	less than a year	sin datos	sin datos
Sally Waterman	Senior Independent Non-Executive Director	less than a year	sin datos	sin datos
Alistair Macdonald	Non-executive Chairman	1.8yrs	UK£17.00k	0.075% £ 15.5k
John Goold	Independent Non-Executive Director	1.3yrs	sin datos	1.55% £ 320.9k
Parag Mallick	Member of Scientific Board	5.1yrs	sin datos	sin datos
Richard Roope	Member of Scientific Board	5.4yrs	sin datos	sin datos
Nora Pashayan	Member of Scientific Board	5.4yrs	sin datos	sin datos
Ola Winqvist	Member of Scientific Board	5.4yrs	sin datos	sin datos

3.5yrs

Permanencia media

55yo

Promedio de edad

Junta con experiencia: La junta directiva de OCY se considera experimentada (3.4 años de antigüedad promedio).

Oncimmune Holdings Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Oncimmune Holdings plc, Annual General Meeting, Feb 26, 2024

Oncimmune Holdings plc Announces Board Changes

Less than half of directors are independent

Oncimmune Holdings plc Announces Changes to the Board

Oncimmune Holdings plc Announces Executive Changes

Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2023

Recent updates

Full year 2023 earnings released: UK£0.085 loss per share (vs UK£0.13 loss in FY 2022)

Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024

Oncimmune Holdings plc, Annual General Meeting, Feb 26, 2024

New minor risk - Financial data availability

Oncimmune Holdings plc Announces Board Changes

Less than half of directors are independent

Oncimmune Holdings plc Announces Changes to the Board

Oncimmune Holdings plc Announces Executive Changes

Freenome Holdings, Inc. acquired Oncimmune Limited and Oncimmune Europe GmbH from Oncimmune Holdings plc (AIM:ONC) for £13 million.

Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2023

Oncimmune Holdings plc Announces Appointment of John Goold as Non-Executive Director

Oncimmune Holdings plc has completed a Follow-on Equity Offering in the amount of £2.1 million.

Less than half of directors are independent

Full year 2022 earnings released: UK£0.14 loss per share (vs UK£0.072 loss in FY 2021)

Now 20% undervalued after recent price drop

Oncimmune Holdings plc Announces Board Changes

Less than half of directors are independent

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Oncimmune Holdings Ordinary Shares to Be Deleted from Other OTC

Oncimmune Holdings plc Announces EarlyCDT Lung Test Approved by Ministry of Health for Aragon, Spain

Full year 2021 earnings released: UK£0.072 loss per share (vs UK£0.13 loss in FY 2020)

Oncimmune Holdings plc Announces the Pre-Publication of the First Results from Its Collaboration with Cedars-Sinai Medical Center in Los Angeles

Oncimmune Holdings plc Presents Clinical Abstracts on Melflufen At the 2021 American Society of Clinical Oncology

Oncopeptides AB (publ) Presents New Clinical and Preclinical Melflufen Data At the Upcoming European Hematology Association Meeting

First half 2021 earnings released: UK£0.041 loss per share (vs UK£0.083 loss in 1H 2020)

New 90-day high: €2.12

Oncimmune Holdings plc to Report First Half, 2021 Results on Feb 15, 2021

Oncimmune Holdings plc Announces Steps Down of Cheung to as a Non-Executive Director, Effective 19 January 2021

New 90-day high: €2.04

Oncimmune Holdings plc Signs Commercial Contracts

New 90-day high: €1.99

Oncimmune Holdings plc, Annual General Meeting, Nov 30, 2020

Full year earnings released - €0.13 loss per share

Annual earnings released: Revenue misses expectations

Oncimmune Holdings plc to Report Fiscal Year 2020 Results on Oct 30, 2020

Oncimmune Holdings plc Initiates U.S. Expanded Access Program with Melflufen in Triple-Class Refractory Multiple Myeloma

Oncimmune Holdings plc announced that it has received £5.25 million in funding from Balderton Capital (UK) LLP and other investors

Oncimmune Holdings plc Signs Collaboration with Genentech

New 90-day high - €1.55

New 90-day high - €1.45

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad